2018 Full Year Results Investor Presentation
Filed with ASX · · 30 pages · English
Watch Mayne Pharma's latest callMayne Pharma Group (ASX:MYX) Q4 2026 Earnings Call · Replay · Aug 26
● The information provided is general in nature and is in summary form only. It is not complete and should be read in conjunction with the company’s audited Financial Statements and market disclosures. This material is not intended to be relied upon as advice to investors or potential investors. Non-IFRS information ● Other than as indicated, the financial information contained in this document is
Mayne Pharma Group Ltd. on 6ix
In the deck
Story so far
Earlier from Mayne Pharma
- 2018 Full Year Results Media Release
- Mayne Pharma acquires generic Efudex in the US
- SUBA-Itraconazole NDA accepted for review by US FDA
- Mayne Pharma opens new US manufacturing facility
- Mayne Pharma launches Amiodarone 200mg tablets in the US
Later from Mayne Pharma
- 2018 AGM Chairmans Address
- 2018 AGM CEOs Speech
- FDA approval of Tolsura (SUBA-itraconazole) capsules
- Tolsura (SUBA-itraconazole) capsule now launched in the US
- Half Year Accounts
Follow Mayne Pharma into a list and get an email when it puts out news.
Follow Mayne Pharma